Peer-Reviewed Literature Synthesis

Lyme Disease Biomarker Atlas

Serologic, cerebrospinal fluid, molecular, and inflammatory biomarkers in Borrelia burgdorferi infection — from early localized disease through disseminated, neuroborreliosis, and post-treatment persistent symptom phenotypes.

Literature Overview

Lyme disease diagnosis relies primarily on two-tier serology per CDC/IDSA guidelines. CSF biomarkers support neuroborreliosis. No validated biomarker distinguishes post-treatment Lyme disease syndrome (PTLDS) from other fatiguing illnesses.

2-tier
CDC-recommended serology
C6
VisE peptide ELISA
CSF
CXCL13 for neuroborreliosis
IgM/IgG
Stage-dependent response

Two-Tier Serology

EIA screening followed by IgM/IgG immunoblot confirmation. Sensitivity improves with disease duration; early EM may be seronegative.

  • EIA (whole-cell or C6)
  • IgM WB: ≥2 of 3 bands
  • IgG WB: ≥5 of 10 bands

CSF & Neuroborreliosis

Intrathecal antibody production and lymphocytic pleocytosis support CNS involvement. CXCL13 is a highly specific CSF chemokine marker.

  • CSF anti-Bb antibody index
  • CSF CXCL13 elevation
  • Lymphocytic pleocytosis

Chronic / PTLDS Phenotype

Persistent symptoms after standard therapy overlap with ME/CFS. Inflammatory and chemokine markers are research-stage only.

  • IL-6, IL-10, IFN-γ alterations
  • CCL19, CXCL13 (serum research)
  • No FDA-validated chronic panel

Searchable Alterations Database

HC = healthy controls; EM = erythema migrans; NB = neuroborreliosis; PTLDS = post-treatment Lyme disease syndrome.

Overlap with ME/CFS & Long COVID

PTLDS and chronic Lyme symptom profiles overlap substantially with ME/CFS (fatigue, PEM, cognitive dysfunction). Shared inflammatory and autonomic biomarkers may appear in both conditions. See the ME/CFS Biomarker Atlas for fatigue-dominant markers not specific to Borrelia exposure.

Stage-dependent serology (CDC two-tier algorithm)

IgM antibodies peak in early disseminated disease (weeks 2–4); IgG antibodies develop over weeks to months and persist for years. Early localized EM (<30 days) may be seronegative — clinical diagnosis with epidemiologic risk is essential. Two-tier testing is not recommended for screening asymptomatic individuals.

Marker / TestDirectionCategoryvs. ComparisonClinical ContextKey Reference

Category Deep Dives

🩸 Two-Tier Serology Panel

  • B. burgdorferi EIA (screening)↑ positive
  • IgG immunoblot (≥5/10 bands)↑ disseminated
  • IgM immunoblot (≥2/3 bands)↑ early
  • C6 peptide ELISA (VisE)↑ sensitive
  • Anti-VlsE antibodies↑

🧠 CSF Neuroborreliosis Markers

  • CSF CXCL13↑ highly specific
  • CSF anti-Bb antibody index↑ intrathecal
  • CSF lymphocytic pleocytosis↑
  • CSF protein elevation↑
  • CSF oligoclonal bands↕ subset

🔥 Inflammatory & Immune Markers

  • IL-6↑ active disease
  • IL-10↑
  • IFN-γ↑
  • CRP↕ variable
  • CCL19↑ research

🔄 Chronic Lyme / PTLDS Research

  • Serum CXCL13↕ research
  • PBMC cytokine profileAltered
  • Anti-neuronal antibodies↕ subset
  • Heart rate variability↓ ME/CFS overlap

Key References

CDC Guidelines

Recommendations for Test Performance and Interpretation — Two-Tier Testing

CDC Lyme Disease — Two-tier serologic testing algorithm
CDC Lab Testing →
Clinical Review

Lyme Disease Diagnosis and Treatment

Lantos PM et al. Infect Dis Clin North Am. 2021 — Serology and clinical staging
DOI: 10.1016/j.idc.2021.05.001 →
Primary Study — C6 ELISA

The C6 Lyme ELISA: A Sensitive and Specific Test

Bacon RM et al. J Infect Dis. 2003 — VisE C6 peptide performance
DOI: 10.1086/376905 →
Primary Study — CSF CXCL13

CXCL13: A Biomarker for Neuroborreliosis

Rupprecht TA et al. Neurology. 2005 — CSF chemokine specificity
DOI: 10.1212/01.wnl.0000185296.27976.4f →
Review — PTLDS

Post-Treatment Lyme Disease Syndrome

Aucott JN et al. Am J Med. 2014 — Persistent symptoms after treatment
DOI: 10.1016/j.amjmed.2014.02.016 →
Review — Co-infections

Tick-Borne Co-infections in Lyme Disease

Swanson SJ et al. Ticks Tick Borne Dis. 2022 — Babesia, Anaplasma, Ehrlichia panels
DOI: 10.1016/j.ttbdis.2022.101987 →
Disclaimer: Educational synthesis only — not medical advice. Lyme diagnosis requires clinical correlation with exposure history and compatible symptoms. Serologic tests have well-documented limitations in early disease. No chronic Lyme biomarker panel is FDA-validated. Consult infectious disease specialists for interpretation.